| Ms Carolyn J King, LCSW-C | |
|
200 Booth St., Upper Bay Counseling, Elkton, MD 21921 | |
| (410) 996-5104 | |
| (410) 996-5725 |
| Full Name | Ms Carolyn J King |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 32 Years |
| Location | 200 Booth St., Elkton, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164673034 | NPI | - | NPPES |
| 922801200 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | Q1-0000429 (Delaware) | Secondary |
| 1041C0700X | Social Worker - Clinical | 09890 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Upper Bay Counseling And Support Services, Inc. | 3971405085 | 12 |
News Archive
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced that new data for its investigational multi-cancer early detection blood test will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I.
Oncolytics Biotech Inc. has announced that it has been granted its 31st U.S. Patent, # 7,476,382, entitled "Reovirus for the Treatment of Neoplasia." The patent includes claims to pharmaceutical compositions containing reovirus.
Six out of ten patients who show common "alarm" symptoms for cancer are not referred for urgent investigation, a largescale new study has revealed.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.
› Verified 6 days ago
| Entity Name | Upper Bay Counseling & Support Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316912652 PECOS PAC ID: 3971405085 Enrollment ID: O20040121000129 |
News Archive
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced that new data for its investigational multi-cancer early detection blood test will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I.
Oncolytics Biotech Inc. has announced that it has been granted its 31st U.S. Patent, # 7,476,382, entitled "Reovirus for the Treatment of Neoplasia." The patent includes claims to pharmaceutical compositions containing reovirus.
Six out of ten patients who show common "alarm" symptoms for cancer are not referred for urgent investigation, a largescale new study has revealed.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Carolyn J King, LCSW-C 1275b W Pulaski Hwy, Elkton, MD 21921-4719 Ph: (410) 620-7161 | Ms Carolyn J King, LCSW-C 200 Booth St., Upper Bay Counseling, Elkton, MD 21921 Ph: (410) 996-5104 |
News Archive
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced that new data for its investigational multi-cancer early detection blood test will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I.
Oncolytics Biotech Inc. has announced that it has been granted its 31st U.S. Patent, # 7,476,382, entitled "Reovirus for the Treatment of Neoplasia." The patent includes claims to pharmaceutical compositions containing reovirus.
Six out of ten patients who show common "alarm" symptoms for cancer are not referred for urgent investigation, a largescale new study has revealed.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.
› Verified 6 days ago
Mrs. Stacy Erin Doney, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 26 Chesters Way, Elkton, MD 21921 Phone: 443-485-8652 | |
April C Maenner, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 111 W High St Ste 109, Elkton, MD 21921 Phone: 443-760-3620 | |
Carrie Bailey, LCSW-C Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 1190 Augustine Herman Hwy, Elkton, MD 21921 Phone: 410-398-0651 | |
Nancy Bramble Reasin, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 102 Saint Louis Dr, Elkton, MD 21921 Phone: 443-350-3322 | |
Mrs. Jamie Lynn Maners, LCSW-C Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 200 Booth St, Elkton, MD 21921 Phone: 410-996-5104 | |
Frances Horzempa, LCSW-C Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 306 W Pulaski Hwy, Elkton, MD 21921 Phone: 410-780-7178 Fax: 410-392-3417 | |
Vivian Ferrara-machado, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 106 Bow St, Elkton, MD 21921 Phone: 410-398-4000 |